{
    "clinical_study": {
        "@rank": "38425", 
        "arm_group": [
            {
                "arm_group_label": "Glimepiride", 
                "arm_group_type": "Experimental", 
                "description": "Starting with Glimepiride. After 3 month, switching to vildagliptin."
            }, 
            {
                "arm_group_label": "Vildagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Starting with vildagliptin. After 3 month, switching to Glimepiride."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to analyze the differences of blood sugar level and glycemic\n      variability between sulfonylurea and DPP-4 inhibitor groups applying CGMS for a chosen\n      number of type 2 DM patients. The investigators also reveal influences of each drugs on\n      cardiovascular risk factors by measuring related biomarkers."
        }, 
        "brief_title": "Effects of Vildagliptine and Glimepiride on Glucose Variability", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Non-Insulin-Dependent", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "We enroll patients with type 2 DM with uncontrolled glucose level on Metformin monotherapy\n      over 1000mg /day (HbA1C over 7%).\n\n      Before drug administration, we conduct basal lab study including CGMS.  After 3 month of\n      random administration of vildagliptin or glimepiride, we check CGMS, glucose levels, CV\n      biomarkers, and estimate hypoglycemic index. We replace with the other drug for 3 months,\n      and then conduct the same measurements. No wash-out period is necessary since result\n      variables are measured after the 3 months of administration for a different drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  with type 2 DM\n\n          -  with uncontrolled glucose level on Metformin monotherapy over 1000mg /day (HbA1C over\n             7%). Provided that the tolerance for metformin is poor, enrollment of patients with\n             lower dose of metfomrin is open.\n\n          -  who have never been prescribed with test drugs, sulfonylurea or DPP-4 inhibitor/GLP-1\n             analogue  in 3 months\n\n          -  who can be applied with CGMS\n\n        Exclusion Criteria:\n\n          -  who has liver function abnormality or renal function abnormality\n\n          -  who has any kind of diseases, operations, medical treatments that can affect glucose\n             levels"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812122", 
            "org_study_id": "CGMS_SU_Gliptin"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Glimepiride", 
                    "Vildagliptin"
                ], 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Glimepiride", 
                    "Vildagliptin"
                ], 
                "intervention_name": "Vildagliptin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Vildagliptin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "email": "yurica514@gmail.com", 
                "last_name": "Kyeong Seon Park, MD", 
                "phone": "+82-2-2072-2228"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS", 
        "overall_contact": {
            "email": "jungjhs@gmail.com", 
            "last_name": "Hye Seung Jung, MD", 
            "phone": "+82-2-2072-0240"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Hye Seung Jung, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Glycemic variability index", 
                "safety_issue": "No", 
                "time_frame": "before and after 3 months of each drug administration"
            }, 
            {
                "measure": "Cardiovascular disease risk factor", 
                "safety_issue": "No", 
                "time_frame": "before and after 3 months of each drug administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812122"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Hye Seung Jung", 
            "investigator_title": "Assistant professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "glucose profile and lipid profile", 
                "safety_issue": "No", 
                "time_frame": "before and after 3 months of each drug administration"
            }, 
            {
                "measure": "hypoglycemic index", 
                "safety_issue": "Yes", 
                "time_frame": "before and after 3 months of each drug administration"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}